List of Relistor drug patents
Relistor is owned by Salix Pharms.
Relistor contains Methylnaltrexone Bromide.
Relistor has a total of 8 drug patents out of which 0 drug patents have expired.
Relistor was authorised for market use on 24 April, 2008.
Relistor is available in solution;subcutaneous dosage forms.
Relistor can be used as treatment of opioid-induced constipation.
The generics of Relistor are possible to be released after 31 December, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(1 year, 12 days from now) | |
| US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 12 days from now) | |
| US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 12 days from now) | |
| US9492445 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US8420663 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US8822490 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9180125 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(7 years from now) | |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 24 April, 2008
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION;SUBCUTANEOUS
RELISTOR family patents
21
United States
8
Japan
7
European Union
5
China
4
Australia
4
Portugal
4
Spain
4
Poland
4
New Zealand
3
Israel
3
Denmark
3
Hong Kong
3
Slovenia
3
Russia
3
Brazil
3
Croatia
3
Cyprus
3
Canada
2
Mexico
2
Korea, Republic of
1
Singapore
1
Argentina
Relistor is owned by Salix.
Relistor contains Methylnaltrexone Bromide.
Relistor has a total of 9 drug patents out of which 0 drug patents have expired.
Relistor was authorised for market use on 19 July, 2016.
Relistor is available in tablet;oral dosage forms.
Relistor can be used as treatment of opioid-induced constipation.
The generics of Relistor are possible to be released after 10 March, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
| US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
| US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
| US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(7 years from now) | |
| US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 19 July, 2016
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
RELISTOR family patents
21
United States
9
Japan
7
New Zealand
6
European Union
5
China
4
Singapore
4
Korea, Republic of
3
Israel
3
Mexico
3
Brazil
3
Poland
2
Australia
2
Hong Kong
2
Russia
2
Argentina
2
Spain
2
Taiwan, Province of China
2
Ukraine
2
Canada
1
South Africa
1
Morocco
1
Hungary
1
Costa Rica
1
Colombia
1
Portugal
1
Guatemala
1
Malaysia
1
Peru
1
Chile
1
Ecuador
1
Georgia
1
EA
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic